## Divalproex Sodium Extended-Release Tablets

| | |
|---|---|
| **Type of Posting** | Revision Bulletin |
| **Posting Date** | 16-Mar-2022 |
| **Official Date** | 17-Mar-2022 |
| **Expert Committee** | Small Molecules 4 |

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Divalproex Sodium Extended-Release Tablets monograph. The purpose of the revision is to add *Dissolution Test 12* to accommodate FDA-approved drug products with different dissolution conditions and tolerances than the existing dissolution test(s).

- *Dissolution Test 12* was validated using the NovaPak Phenyl brand of column with L11 packing. The typical retention time for valproic acid is about 5.5 min.

The Divalproex Sodium Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Robyn Fales, Senior Scientist I (240-221-2047 or rnp@usp.org).